The negative polls come as the Congressional Budget Office estimates the bill would lead to 23 million more uninsured people. » Read More
Blue Cross and Blue Shield NC says it would have asked for just an 8.8 percent increase, and not almost 24 percent. » Read More
The Republican Obamacare replacement bill includes provisions that could allow insurers to eliminate essential health benefits in plans. » Read More
By: Bertha Coombs
UnitedHealth Group's Optum unit has signed a multiyear agreement with Merck to develop a better way to reimburse drugmakers. » Read More
J&J was ordered to pay $55 million to a woman who said that using the company's talc-powder products caused her to develop cancer.
Martin Shkreli made an appearance at the U.S. Federal Court in Brooklyn for a hearing related to securities fraud charges.
Pfizer has approached U.S. cancer drug maker Medivation to express interest in an acquisition, raising the possibility of a bid.
Pfizer reported a 19.7 percent rise in quarterly revenue, boosted by sales of its new treatments for cancer and its Hospira acquisition.
Quintiles Transnational and IMS Health said they would merge, creating a company with a market value of more than $17.6 billion.
Presentations have always been stressful, but failing tech can affect productivity and mental health, according to research into stress.
GlaxoSmithKline CEO Andrew Whitty thinks his company's success has been a product of being patient and investing in innovation.
African-Americans were much less likely to undergo potentially life-saving surgery in Georgia if they lived in heavily segregated areas.
Hedge fund manager Bill Ackman defended his key holding Valeant Pharmaceuticals on Monday, as its shares continued to tumble.
Sarepta Therapeutics shares soared Monday after the stock was upgraded to "outperform" at Oppenheimer.
The hedge fund manager says he aims to bring a "meaningful" turnaround and touted embattled drugmaker Valeant's new chief executive.
Berkshire Hathaway Vice-Chairman Charlie Munger had some harsh words to say about Valeant Pharmaceuticals.
Biotech stocks dragged on the market Friday, and some "Fast Money" traders contended the pain may not be done.
A top public health official told CNBC that the U.S. could very well see more instances of the Zika virus.
Puerto Rico's health secretary says the island has recorded its first Zika-related death amid an outbreak of the mosquito-borne virus.
Gilead Sciences fell nearly 8 percent, dragging down the S&P 500’s health care sector.
Quest Diagnostics said it has received emergency authorization from U.S. regulators to sell the first commercially developed diagnostic test for Zika.
Diagnostic test maker Alere said it has rejected a request by Abbott Laboratories to terminate the $5.8 billion deal to buy Alere for a breakup fee.
A huge Hewlett Packard Enterprise project hopes to use massive data sets to better craft medical treatments and medicines for patients.
If there are inflation winds in the air, it would be hard to tell by worker paychecks.
Get the best of CNBC in your inbox